Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy

Journal of Immunotherapy

Volumn 34, Issue 2, 2011, Pages 196-201

  Bierer, Stefan ^a   Hoffmeister, Ina ^a   Gerss, Joachim ^a   Herrmann, Edwin ^a   Wülfing, Christian ^a   Sibrowski, Walter ^a   Hertle, Lothar ^a   Kelsch, Reinhard ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

human leukocyte antigen; immunotherapy; prognostic factors; renal cell carcinoma; therapy

Indexed keywords

FLUOROURACIL; HLA ANTIGEN CLASS 2; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA FINGERPRINTING; FEMALE; GENOTYPE; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; METASTATIC RENAL CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79953085641     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182027748     Document Type: Article

References (22)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356: 125-134. (Pubitemid 46089673)
3. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. (Pubitemid 46849157)
4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111. (Pubitemid 350296300)
5. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
6. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57.
7. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immu nological and clinical responses. Clin Cancer Res. 2004;10: 4699-4708. (Pubitemid 38955520)
8. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
9. Bain C, Merrouche Y, Puisieux I, et al. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer. 1997;75:283-286. (Pubitemid 27019575)
10. Franzke A, Buer J, Probst-Kepper M, et al. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother Radiopharm. 2001;16:401-409. (Pubitemid 33151117)
11. Ellerhorst JA, Hildebrand WH, Cavett JW, et al. Hetero-zygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J Urol. 2003;169:2084-2088. (Pubitemid 36576723)
12. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177-186. (Pubitemid 30205372)
13. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996;14:2410-2411. (Pubitemid 26264899)
14. Coppin C. Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther. 2008;8:907-919.
15. Schrader AJ, Hofmann R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anticancer Drugs. 2008;19:235-245.
16. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004;4: 455-468. (Pubitemid 38480546)
17. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997;3(suppl 1):S92-S97.
18. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20: 289-296. (Pubitemid 34032623)
19. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488-495. (Pubitemid 41232570)
20. Kwak C, Park YH, Jeong CW, et al. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol. 2007;95:317-323. (Pubitemid 46355508)
21. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721. (Pubitemid 40685588)
22. Lee S, Baig M, Rusciano V, et al. Survival advantage in patients treated with high-dose interleukin-2 (HDIL2) for metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2009;27(suppl):e16039.